BioMarin July calls active BioMarin July 65, 70 and 75 calls are active on total call volume of 8000 contracts (300 puts). July call option implied volatility is at 55, October is at 42; compared to its 26-week average of 42 according to Track Data. Active call volume suggests traders taking positions for price movement.
BioMarin submits Paragraph IV notice letter for Kuvan tablets to the FDA BioMarin announced that a Paragraph IV Certification Notice Letter was submitted to the FDA in connection with an Abbreviated New Drug Application to the FDA for approval to market a generic version of Kuvan Tablets, although it has not yet received notice of the certification. BioMarin will evaluate the Paragraph IV certification when it receives the Notice Letter and intends to enforce its intellectual property rights. Once the lawsuit is filed, the 30 month stay period will begin as of the date BioMarin was notified of the filing.